Boston Scientific (BSX) Operating Leases (2019 - 2020)

Boston Scientific (BSX) posted quarterly Operating Leases of $256.0 million for Q3 2020, down 2.66% on a QoQ basis from $263.0 million in Q2 2020.

Boston Scientific (BSX) Operating Leases (2019 - 2020) Analysis & Trends

Boston Scientific has reported Operating Leases for 2 years, with the latest figure at $256.0 million in Q3 2020.

Operating Leases for Q3 2020 came in at $256.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2020 was $256.0 million (changed N/A YoY), and the FY2019 annual result was $276.0 million, changed N/A from the prior year.
Operating Leases fell to $256.0 million in Q3 2020, from $263.0 million in the prior quarter.
Over five years, Operating Leases peaked at $276.0 million in Q4 2019 and troughed at $256.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	200.19 Bn	194.59 Bn	7.27 Bn
2	Stryker	129.95 Bn	126.47 Bn	4.50 Bn
3	Medtronic	120.06 Bn	110.84 Bn	6.41 Bn
4	Boston Scientific	74.14 Bn	73.60 Bn	3.85 Bn
5	Edwards Lifesciences	52.74 Bn	48.49 Bn	1.35 Bn
6	Dexcom	34.60 Bn	32.65 Bn	830.00 Mn
7	GE HealthCare Technologies	34.20 Bn	32.10 Bn	2.18 Bn
8	Koninklijke Philips	26.46 Bn	23.13 Bn	4.55 Bn
9	Steris	23.25 Bn	22.77 Bn	684.20 Mn
10	Zimmer Biomet Holdings	19.36 Bn	18.95 Bn	1.54 Bn

Download Data